Intermittent Erector Spinae Plane Block Via Subcutaneous Port for Cancer Pain
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorHanoi Medical University
About this trial
Cancer-related pain is a common and challenging problem in patients with lung cancer, often requiring long-term pain management. Conventional pain treatments, including systemic medications, may not provide adequate relief or may cause significant side effects.
The erector spinae plane (ESP) block is a regional anesthesia technique that can help reduce pain by delivering local anesthetic near the nerves supplying the chest wall. This study aims to evaluate the effectiveness and safety of intermittent ESP block administered through a subcutaneous port for controlling cancer-related pain in patients with lung cancer.
Eligible patients with lung cancer and moderate to severe pain will receive intermittent ESP block injections via a subcutaneous port as part of their pain management plan. Pain intensity, analgesic requirements, and potential side effects will be assessed over time.
The results of this study may help determine whether intermittent ESP block via a subcutaneous port is a useful and feasible option for improving pain control and quality of life in patients with lung cancer.
Eligibility criteria
Qualifiers
Adult patients diagnosed with advanced-stage lung cancer who are currently receiving palliative care only.
Presence of chronic cancer-related chest pain lasting longer than 1 month, localized to the thoracic region due to chest wall invasion, pleural involvement, or bone metastases.
Performance status ≤ 3 according to the Eastern Cooperative Oncology Group (ECOG), allowing placement of a subcutaneous port and maintenance of local anesthetic administration.
Inadequate pain control with conventional analgesic therapies or clinical indication for the addition of regional analgesia.
Disqualifiers
Chest pain with radiation to the upper extremities, neck, or shoulder, suggestive of non-localized thoracic pain.
Severe hepatic or renal dysfunction, or severe heart failure (New York Heart Association class III-IV).
Local infection at the injection or port placement site, or uncontrolled systemic infection.
Severe cachexia or insufficient subcutaneous tissue that does not allow safe coverage of the subcutaneous port.
Trial design
Treatments tested in this trial
- Erector Spinae Plane Block
Treatment groups
180 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov